Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Dollar change -0.21
Percentage change -2.53	%

Held by: IJR CALF VTI VB IWM VXF VBK IBB IWN IJT

Index	RUT	P/E	-	EPS (ttm)	-6.51	Insider Own	3.15%	Shs Outstand	156.35M	Perf Week	5.88%
Market Cap	1.27B	Forward P/E	10.16	EPS next Y	0.80	Insider Trans	-5.31%	Shs Float	151.60M	Perf Month	-3.69%
Income	-1002.24M	PEG	-	EPS next Q	0.20	Inst Own	107.50%	Short Float	14.48%	Perf Quarter	-39.14%
Sales	442.74M	P/S	2.86	EPS this Y	110.57%	Inst Trans	-3.30%	Short Ratio	4.78	Perf Half Y	-10.00%
Book/sh	-2.21	P/B	-	EPS next Y	16.99%	ROA	-127.54%	Short Interest	21.95M	Perf Year	-23.37%
Cash/sh	0.59	P/C	13.76	EPS next 5Y	-	ROE	-654.88%	52W Range	7.53 - 15.70	Perf YTD	-29.20%
Dividend Est.	-	P/FCF	6.92	EPS past 5Y	-28.37%	ROI	-601.74%	52W High	-48.41%	Beta	0.56
Dividend TTM	-	Quick Ratio	0.84	Sales past 5Y	5.56%	Gross Margin	99.64%	52W Low	7.57%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	0.84	EPS Y/Y TTM	-668.17%	Oper. Margin	39.17%	RSI (14)	41.63	Volatility	3.64% 3.50%
Employees	267	Debt/Eq	-	Sales Y/Y TTM	7.83%	Profit Margin	-226.37%	Recom	1.17	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-102.65%	Payout	-	Rel Volume	0.40	Prev Close	8.31
Sales Surprise	0.07%	EPS Surprise	-105.00%	Sales Q/Q	9.66%	Earnings	Feb 15 BMO	Avg Volume	4.59M	Price	8.10
SMA20	0.01%	SMA50	-19.54%	SMA200	-21.97%	Trades		Volume	1,853,345	Change	-2.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral
Jul-23-18	Initiated	H.C. Wainwright	Sell	$12.50
May-09-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-06-17	Downgrade	Mizuho	Buy → Neutral	$16
Jul-21-17	Downgrade	JP Morgan	Overweight → Neutral
May-03-17	Initiated	Wells Fargo	Outperform

Show Previous Ratings

Apr-21-24 10:39AM	5 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Mar-28-24 07:30AM	Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) (Business Wire)
Mar-05-24 01:05PM	Its Time! 3 Failing Biotech Stocks to Sell Right Now (InvestorPlace)
Feb-29-24 04:19PM	Ironwood Pharmaceuticals Ran Up 38% Over Three Months And Just Lost It All (Investor's Business Daily) -37.63%
08:37AM	Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today? (InvestorPlace)
06:26AM	Loading…
06:26AM	UPDATE 1-Ironwood's bowel disease treatment meets main goal in late-stage trial (Reuters)
06:08AM	Ironwood says bowel disease treatment meets main goal in late-stage trial (Reuters)
06:00AM	Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire)
Feb-23-24 07:30AM	Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference (Business Wire)
Feb-16-24 10:15AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:36AM	Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally (Zacks)
Feb-15-24 10:45PM	Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4 (Zacks)
07:26AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance (Business Wire)
08:50AM	Loading…
Feb-05-24 08:50AM	Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-01-24 04:01PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call (Business Wire)
Jan-23-24 09:55AM	Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet (Zacks)
Jan-08-24 07:00PM	Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation (Business Wire)
06:00AM	Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance (Business Wire)
Jan-03-24 04:01PM	Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 04:01PM	Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-21-23 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-10-23 02:45PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript (Insider Monkey)
11:09AM	Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises (Zacks)
Nov-09-23 10:25PM	Q3 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:39AM	Ironwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year Guidance (GuruFocus.com)
07:46AM	Top 11 Extreme Value Stocks To Buy (Insider Monkey)
07:22AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2023 Results (Business Wire)
Oct-26-23 04:01PM	Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call (Business Wire)
Oct-23-23 07:30AM	Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting (Business Wire)
Oct-17-23 12:02PM	Decoding Ownership and Performance: Ironwood Pharmaceuticals Inc(IRWD) (GuruFocus.com)
Oct-16-23 06:00AM	Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week (Business Wire)
Oct-05-23 07:30AM	Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old (Business Wire)
Oct-03-23 11:43AM	Ironwood Pharmaceuticals (IRWD): A Hidden Gem or a Potential Risk? An In-Depth Look at Its Valuation (GuruFocus.com)
Oct-01-23 07:15AM	Here's How to Lock in a Trade on a Promising Biopharma Name (TheStreet.com)
Sep-26-23 11:48AM	Unveiling Ironwood Pharmaceuticals (IRWD)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-20-23 07:36AM	Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Sep-19-23 12:08PM	Ironwood Pharmaceuticals Inc (IRWD): A Deep Dive into Its Performance Potential (GuruFocus.com) +7.55%
11:39AM	Ironwood Pharmaceuticals (IRWD): A Comprehensive Analysis of Its Market Value (GuruFocus.com)
Sep-12-23 08:32AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-07-23 11:30AM	Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report? (Zacks)
Aug-12-23 08:50AM	Is There An Opportunity With Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 49% Undervaluation? (Simply Wall St.)
Aug-09-23 09:24AM	Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises (Zacks) -6.79%
Aug-08-23 11:12PM	Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.16%
11:05AM	Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates (Zacks)
09:56AM	Ironwood: Q2 Earnings Snapshot (AP Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-25-23 04:01PM	Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call (Business Wire)
Jun-29-23 08:30AM	Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares (Business Wire)
Jun-21-23 08:00PM	IRWD: Lowering target price to $11.00 (Argus Research)
Jun-16-23 07:00AM	Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio (Business Wire)
Jun-13-23 09:18AM	Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion (Zacks)
Jun-12-23 04:05PM	Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old (Business Wire)
09:54AM	Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround (Motley Fool)
May-25-23 10:32AM	Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates (Zacks)
May-23-23 12:07PM	Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6% (Zacks)
May-22-23 05:43PM	Why Ironwood Pharmaceuticals Stock Bumped Higher Today (Motley Fool)
04:08PM	VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 Billion (Investor's Business Daily)
01:11PM	Ironwood spends $1B to acquire Swiss biotech (American City Business Journals)
12:02PM	Why Shares of VectivBio Holding Are Up Today (Motley Fool)
08:40AM	Ironwood Pharmaceuticals to Buy VectivBio in $1 Billion Deal. The Sector Is Hot for M&A. (Barrons.com)
07:24AM	UPDATE 1-Ironwood Pharma to acquire VectivBio for $1.15 bln (Reuters)
07:22AM	Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy (Reuters)
06:57AM	Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases (Business Wire)
May-09-23 04:01PM	Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference (Business Wire)
May-08-23 07:30AM	Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023 (Business Wire)
May-05-23 09:31AM	Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up (Zacks)
May-04-23 08:55AM	Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:00AM	Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance (Business Wire)
Apr-26-23 08:00PM	IRWD: What does Argus have to say about IRWD? (Argus Research)
Apr-24-23 07:30AM	Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old (Business Wire)
Apr-20-23 04:01PM	Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call (Business Wire)
Mar-22-23 02:53PM	Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
Mar-14-23 02:56AM	Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength? (Zacks)
Mar-02-23 07:09AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Could Be 40% Below Their Intrinsic Value Estimate (Simply Wall St.)
Feb-27-23 04:01PM	Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-23 07:40AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-17-23 11:11AM	Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases (Zacks)
Feb-16-23 08:35AM	Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results (Business Wire)
Feb-15-23 11:09AM	Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others (Zacks)
Feb-14-23 10:00AM	BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:20AM	Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA (Zacks)
Feb-13-23 07:30AM	Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old (Business Wire)
Feb-10-23 07:40AM	15 Small Innovative Companies According to the Media (Insider Monkey)
Feb-09-23 10:01AM	Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-04-23 09:40AM	3 No-Brainer Stocks to Buy Right Now for Less Than $25 (Motley Fool)
Feb-02-23 04:01PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call (Business Wire)
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-16-23 05:36AM	Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders are up 3.7% this past week, but still in the red over the last five years (Simply Wall St.)
Jan-09-23 06:00AM	Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance (Business Wire) -10.99%
Jan-04-23 04:01PM	Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-22 11:30AM	Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-22-22 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference (Business Wire)
Nov-09-22 07:47AM	Ironwood Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-04-22 12:13PM	Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows (Zacks)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shetzline Michael	CMO,SVP,Head-Res&Drug	Mar 08 '24	Option Exercise	0.00	34,936	0	429,847	Mar 12 04:05 PM
John Minardo	Chief Legal Officer	Mar 08 '24	Option Exercise	0.00	32,752	0	311,975	Mar 12 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Mar 08 '24	Option Exercise	0.00	120,298	0	1,217,948	Mar 12 04:05 PM
Davis Andrew	SVP, Chief Business Officer	Mar 08 '24	Option Exercise	0.00	37,120	0	310,756	Mar 12 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Mar 08 '24	Option Exercise	0.00	37,120	0	338,853	Mar 12 04:05 PM
Duane Jon R	Director	Mar 06 '24	Buy	8.70	6,920	60,204	121,028	Mar 08 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Mar 04 '24	Buy	9.38	10,684	100,216	301,733	Mar 06 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 12 '24	Sale	15.24	177,164	2,699,979	832,774	Feb 14 08:35 PM
John Minardo	Chief Legal Officer	Feb 12 '24	Sale	15.24	47,380	722,071	224,796	Feb 14 09:01 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	Feb 12 '24	Sale	15.24	38,618	588,538	340,484	Feb 14 08:53 PM
Davis Andrew	SVP, Chief Business Officer	Feb 12 '24	Sale	15.24	9,846	150,053	208,324	Feb 14 08:42 PM
Silver Ronald	Principal Accounting Officer	Feb 12 '24	Sale	15.24	7,908	120,518	134,264	Feb 14 08:50 PM
Kessler Marla L	Director	Dec 14 '23	Sale	11.19	9,926	111,072	96,572	Dec 18 04:09 PM
Davis Andrew	SVP, Chief Business Officer	Nov 20 '23	Sale	9.69	3,287	31,851	217,374	Nov 22 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Sep 15 '23	Buy	8.32	36,072	300,119	188,730	Sep 18 05:07 PM
John Minardo	Chief Legal Officer	Aug 14 '23	Sale	10.04	7,045	70,732	192,195	Aug 16 04:20 PM
Silver Ronald	Principal Accounting Officer	Aug 14 '23	Sale	10.04	1,976	19,839	134,172	Aug 16 04:21 PM
MCCOURT Thomas A	Chief Executive Officer	May 30 '23	Sale	10.70	26,632	284,962	758,284	Jun 01 05:45 PM
MCCOURT Thomas A	Chief Executive Officer	May 22 '23	Sale	10.12	36,000	364,320	784,916	May 24 04:05 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	May 22 '23	Sale	10.12	10,324	104,479	321,131	May 24 04:05 PM
Davis Andrew	SVP, Chief Business Officer	May 22 '23	Sale	10.12	6,305	63,807	219,327	May 24 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	May 08 '23	Sale	10.62	21,148	224,592	820,916	May 10 04:05 PM

Open in Screener

CYCN

Cyclerion Therapeutics Inc

Apr 24 • 04:00PM ET

2.77

Dollar change +0.03
Percentage change 1.09	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CYCN Cyclerion Therapeutics Inc daily Stock Chart

Held by: VXF ONEQ

Index	-	P/E	-	EPS (ttm)	-9.07	Insider Own	27.57%	Shs Outstand	2.47M	Perf Week	-12.89%
Market Cap	7.51M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.96M	Perf Month	-13.44%
Income	-21.02M	PEG	-	EPS next Q	-	Inst Own	39.47%	Short Float	1.13%	Perf Quarter	-22.52%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	19.81%	Short Ratio	7.23	Perf Half Y	-17.56%
Book/sh	4.56	P/B	0.61	EPS next Y	-	ROA	-119.14%	Short Interest	0.02M	Perf Year	-49.64%
Cash/sh	2.79	P/C	0.99	EPS next 5Y	-	ROE	-172.37%	52W Range	1.75 - 6.75	Perf YTD	-17.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.06%	ROI	-186.17%	52W High	-58.96%	Beta	1.84
Dividend TTM	-	Quick Ratio	3.85	Sales past 5Y	-33.97%	Gross Margin	-	52W Low	58.28%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	3.85	EPS Y/Y TTM	55.26%	Oper. Margin	0.00%	RSI (14)	41.37	Volatility	5.75% 7.22%
Employees	1	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	79.35%	Payout	-	Rel Volume	0.23	Prev Close	2.74
Sales Surprise	-13.92%	EPS Surprise	-3.33%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	3.05K	Price	2.77
SMA20	-12.20%	SMA50	-11.14%	SMA200	-14.88%	Trades		Volume	717	Change	1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
07:00AM	Loading…
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire)
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
06:34AM	Loading…
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
09:30AM	Loading…
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire)
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire)
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire)
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire)
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)
Mar-23-20 06:50AM	Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock? (Simply Wall St.) +18.94%
Jan-13-20 07:00AM	Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases (GlobeNewswire) +10.26%
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO (Benzinga)
Dec-24-19 08:17AM	Can Cyclerion Therapeutics (NASDAQ:CYCN) Afford To Invest In Growth? (Simply Wall St.) +6.87%
Dec-23-19 07:00AM	Cyclerion to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-19 03:43PM	Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds (Insider Monkey)
Nov-27-19 07:00AM	Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference (GlobeNewswire)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	Aug 09 '23	Sale	3.40	8	27	0	Aug 11 04:25 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

IRWD

Ironwood Pharmaceuticals Inc

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience